Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
about
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Clinical use and applications of histone deacetylase inhibitors in multiple myelomaDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsInnovative agents in multiple myelomaEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesPhase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting ApproachesEpigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Lenalidomide and vorinostat maintenance after autologous transplant in multiple myelomaRole of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and PanobinostatUnderstanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.An update on the use of lenalidomide for the treatment of multiple myeloma.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.Promising therapies in multiple myeloma.The biological significance of histone modifiers in multiple myeloma: clinical applications
P2860
Q26740359-BB34C210-0789-48D4-82BD-6F0ED1D16C2BQ26745930-36730E04-6A47-40BC-AC40-F9D5B87155E9Q26749421-52FB9B4C-9B10-48D1-9C50-4AA23E3D4BA2Q27022493-6D422DC9-32CB-4479-B4CE-4944A7A99AA0Q27026478-D38F3706-2E8F-4E4B-9F19-5C6B89CF79F4Q33423168-EE09F536-2BAB-451A-9246-B58D5876B655Q33436890-6D5B6B84-5E7D-4C24-A17D-BA1C2B2568D0Q33658023-6A8F9D74-FDFC-40EB-90E6-39443084B1D7Q35726371-D83756DE-23F5-40C9-8450-95B6F0831D4BQ36145310-49B07819-C3CD-440A-97C8-028A212D67FEQ37199772-6C38766C-D0DF-4C60-9426-76ACB647F93CQ38255333-45375BBE-F459-441E-8435-5CBF9C9A21DEQ38545607-C72AA0FF-5F93-4165-A8C4-2FA7C13079DDQ38630472-3EDA5CC8-25C3-4B15-95CC-205D509BE91DQ38813504-1793D605-B65D-4726-A185-202B55456F58Q39234159-C06BE1BF-D562-4780-9562-751C4F17D2EEQ41316676-556D20ED-C8B5-488E-A132-FFE075EE807EQ42581682-249D48CF-791D-4EAF-B9AA-15071D82D492Q58718492-752F681A-C885-496C-B3CB-689341A1D8D0
P2860
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Vorinostat in combination with ...... r refractory multiple myeloma.
@en
type
label
Vorinostat in combination with ...... r refractory multiple myeloma.
@en
prefLabel
Vorinostat in combination with ...... r refractory multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
Vorinostat in combination with ...... or refractory multiple myeloma
@en
P2093
C Mitsiades
K C Anderson
P Richardson
P2860
P2888
P356
10.1038/BCJ.2014.1
P577
2014-02-21T00:00:00Z
P5875
P6179
1039469219